EY Smart Reviewer allows pharmaceutical and medical technology companies to automate the medical, legal, and regulatory review process and shorten review and approval timelines thereby increasing the speed that essential medicines reach the market. The software uses AI and machine learning to improve compliance by increasing the objectivity and consistency of reviews, according to EY.

The software comprises 12 machine-learning modules, with new modules being developed and added, the company said. The reviewer is currently available in English but will be available in French, German, Spanish, Italian, Japanese, and Chinese by early 2022.

How can the cell and gene therapy field industrialize collaboration?
Adlai Goldberg, the global life sciences digital, social, and commercial innovation leader at Ernst & Young, led a workshop on "Unlocking the Power...